ArticleNature communications2024
Prostaglandin E
Abstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Imaging-guided COX-2 inhibition synergizes with photodynamic immunogenic cell death to potentiate checkpoint blockade in colon cancer.International journal of pharmaceutics: X · 2026Article
- Platelets as non-canonical immune regulatory nodes: orchestrating T cell dysfunction and immunotherapy resistance in cancer.Apoptosis : an international journal on programmed cell death · 2026Review
- Prophylactic and therapeutic effects of aspirin in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Nitric oxide dependent metabolic and genetic dysregulation in metastatic triple-negative breast cancer.The Journal of biological chemistry · 2026Article
- Tumor-Driven Inflammation Promotes Tumor Growth: A Focus on Anti-Inflammatory Cancer Treatments.Diseases (Basel, Switzerland) · 2026Review
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- The interplay between lipid metabolism, cancer progression and anti-cancer immunity.Experimental & molecular medicine · 2026Review
- Tumor-platelet cross talk in cancer: mechanisms, thrombotic risk, and translational opportunities.Blood advances · 2026Review
- Tumoral Metabolism at the Intersection of Oncogene Signaling, Epigenetics and Immunology: Emerging Therapeutic Strategies in Cancer.Current issues in molecular biology · 2026Review
- TGF-β-producing tBregs are associated with poor survival rates in PTGS2-high cancers.Cell death & disease · 2026Article
- Therapy-Driven Molecular Evolution of Bladder Cancer: Roles of Cellular Plasticity and Tumor Microenvironment.International journal of molecular sciences · 2026Review
- Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals in triple-negative breast cancer.Signal transduction and targeted therapy · 2026Article
- Single-cell and spatial transcriptomics reveal an arachidonic acid-related cellular atlas in lung adenocarcinoma.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Aspirin alters molecular crosstalk between prostaglandin, apoptosis, and invasion pathways in colorectal cancer.BMC cancer · 2026Article
- Metabolic regulation of tumor-associated macrophage function and immunotherapy in cancer.Cancer biology & medicine · 2026Review
- Targeting the COX-2/PGECancer immunology, immunotherapy : CII · 2026Review
- Migrasome-transported PTGES amplifies the PGE2 cascade in SPP1Nature communications · 2026Article
- Targeting inflammatory microenvironments: overcoming therapy resistance and immunosuppression.Molecular cancer · 2026Review
- Fatty acid uptake mediated by FABP4 promotes the formation of CD8Oncogenesis · 2026Article
- Engineering with EP2/EP4 knockout and IL-15 transpresentation renders stem cell-derived NK cells self-persistent and resistant to PGE2 inhibition.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Siwakorn PunyawatthananukoolDepartment of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan.
Ryuma MatsuuraDepartment of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan.
Thamrong WongchangDepartment of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan.
Nao KatsuradaDepartment of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan.
Tatsuaki TsuruyamaDepartment of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan.
Masaki TajimaDivision of Integrated High-Order Regulatory Systems, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, 606-8501, Japan.ORCID 0000-0003-3407-0229
Yutaka EnomotoMolecular Pharmacology of Malignant Diseases, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, 113-0033, Japan.
Toshio KitamuraMolecular Pharmacology of Malignant Diseases, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, 113-0033, Japan.ORCID 0000-0001-7855-1767
Masahiro KawashimaDepartment of Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan.ORCID 0000-0002-4738-8351
Masakazu ToiDepartment of Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan.ORCID 0000-0003-1488-9958
Koji YamanoiDepartment of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan.ORCID 0000-0002-1240-5422
Junzo HamanishiDepartment of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan.ORCID 0000-0002-7750-0623
Shigeo HisamoriDepartment of Gastrointestinal Surgery, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan.
Kazutaka ObamaDepartment of Gastrointestinal Surgery, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan.
Varodom CharoensawanDivision of Medical Bioinformatics, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.ORCID 0000-0002-2199-4126
Dean ThumkeoDepartment of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan.ORCID 0000-0002-4513-8455
Shuh NarumiyaDepartment of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan. narumiya.shuh.7a@kyoto-u.ac.jp.ORCID 0000-0001-8062-6529
Funding
Japan Agency for Medical Research and Development (AMED) 21gm40100009h0002
Abstract
While prostaglandin E
Indexed as
DinoprostoneEnergy MetabolismReceptors, Prostaglandin E, EP2 SubtypeReceptors, Prostaglandin E, EP4 SubtypeRibosomesSignal TransductionTumor MicroenvironmentAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleGlycolysisHumansImmune ToleranceMacrophagesMiceDinoprostonePTGER2 protein, humanPTGER4 protein, humanReceptors, Prostaglandin E, EP2 SubtypeReceptors, Prostaglandin E, EP4 Subtype
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.